Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
03/01/2023* -- Results Q4 2022 -- -0.96 --
11/02/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/02/2022 -- Results Q3 2022 -0.80 -0.74 -8.25%
08/02/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/02/2022 -- Results Q2 2022 -1.18 -0.60 -96.10%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.56 -1.03 45.63%
*Estimated Date/Time

Earnings

Next Report Date 03/01/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/02/2022
Beat/Miss Upgrade
Return Since 8.43%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
URL https://www.sarepta.com
Investor Relations URL https://investorrelations.sarepta.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Value
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
166.6%
-28.90%
102.8%
96.14%
18.24%
32.12%
-47.18%
36.57%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.17%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
46.07%
--
-27.18%
-17.04%
-49.64%
3.57K%
-21.18%
-53.63%
90.50%
--
--
--
--
--
--
--
-71.72%
-2.95%
-60.23%
239.3%
-42.61%
57.96%
12.85%
30.48%
29.88%
As of December 01, 2022.

Profile

Edit
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
URL https://www.sarepta.com
Investor Relations URL https://investorrelations.sarepta.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Value
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
DBMCX 88.16M USD 3.56%
FBT 43.42M USD 3.04%
JFNSX 108.46M USD 2.74%
BMEZ 40.38M USD 2.02%
ATHGX 92.78M USD 1.95%
FXH 30.02M USD 1.95%
JGMCX 105.08M USD 1.52%
XBI 87.60M USD 1.13%
FSPHX 81.80M USD 1.02%
IBB 78.59M USD 0.91%
VISGX 141.91M USD 0.51%
VBK 141.91M USD 0.51%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SRPT Tweets